Apriso granulated mesalamine: Phase III data

In a double-blind, U.S. Phase III trial in 305 patients with UC in remission, 1.5 g once-daily Apriso met the primary endpoint of a significantly higher

Read the full 260 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE